Best in BezuCLAStinib (11/2-11/15)

from In the Pipeline · host Tyler Vaglivelo

If you have any questions, please reach out at [email protected]. Thank you for listening!Topics:Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 MonthsRelmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder CancerUpdate on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study

Episode metadata supplied by the publisher feed · Published Nov 21, 2025

Embed this episode

Attribution link and audio player

Ready to play

Best in BezuCLAStinib (11/2-11/15)

0:00 12:49

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of In the Pipeline?

This episode is 12 minutes long.

When was this In the Pipeline episode published?

This episode was published on November 21, 2025.

Can I download this In the Pipeline episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!